Georgia Ragia

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Atrial Fibrillation

End Stage Renal Disease

Genetic Diversity

Long Non Coding Rna

Top Venues

Pharmacogenomics

Journal of personalized medicine

Current drug metabolism

European journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Georgia Ragia, Eirini Biziota, Triantafyllia Koukaki, Kyriakos Amarantidis, Vangelis G Manolopoulos
MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations. Pharmacogenomics 25 (2) (2024)
Georgia Ragia, Thomas Thomopoulos, Georgios K Chalikias, Athanasios Trikas, Dimitrios N Tziakas, Vangelis G Manolopoulos
Circulating microRNAs and DNA Methylation as Regulators of Direct Oral Anticoagulant Response in Atrial Fibrillation and Key Elements for the Identification of the Mechanism of Action (miR-CRAFT): Study Design and Patient Enrolment. Journal of personalized medicine 14 (6) (2024)
Georgia Ragia, Eirini Biziota, Triantafyllia Koukaki, Kyriakos Amarantidis, Vangelis G Manolopoulos
MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations. Pharmacogenomics (2024)
Georgia Ragia, Myria Pallikarou, Yiota Manolopoulou, Theofanis Vorvolakos, Vangelis G Manolopoulos
Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation. Pharmacogenomics 25 (5-6) (2024)
Georgia Ragia, Myria Pallikarou, Yiota Manolopoulou, Theofanis Vorvolakos, Vangelis G Manolopoulos
Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation. Pharmacogenomics 25 (5-6) (2024)
Vangelis G Manolopoulos, Georgia Ragia
Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD. Current drug metabolism (2024)
Georgia Ragia, Eirini Biziota, Triantafyllia Koukaki, Kyriakos Amarantidis, Vangelis G Manolopoulos
MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations. Pharmacogenomics 25 (2) (2024)
Georgia Ragia, Eirini Biziota, Triantafyllia Koukaki, Kyriakos Amarantidis, Vangelis G Manolopoulos
MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations. Pharmacogenomics 25 (2) (2024)
Georgia Ragia, Myria Pallikarou, Yiota Manolopoulou, Theofanis Vorvolakos, Vangelis G Manolopoulos
Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation. Pharmacogenomics (2024)
Georgia Ragia, Thomas Thomopoulos, Georgios K Chalikias, Athanasios Trikas, Dimitrios N Tziakas, Vangelis G Manolopoulos
Circulating microRNAs and DNA Methylation as Regulators of Direct Oral Anticoagulant Response in Atrial Fibrillation and Key Elements for the Identification of the Mechanism of Action (miR-CRAFT): Study Design and Patient Enrolment. Journal of personalized medicine 14 (6) (2024)
Vangelis G Manolopoulos, Georgia Ragia
Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD. Current drug metabolism 25 (2) (2024)
Georgia Ragia, Vangelis G Manolopoulos
The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine? Pharmacogenomics 23 (16) (2022)
Charalampia Ioannou, Georgia Ragia, Ioanna Balgkouranidou, Nikolaos Xenidis, Kyriakos Amarantidis, Triantafyllia Koukaki, Eirini Biziota, Stylianos Kakolyris, Vangelis G Manolopoulos
Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity. Pharmacogenomics 22 (11) (2021)
Georgia Ragia, Vangelis G Manolopoulos
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. European journal of clinical pharmacology 76 (12) (2020)
Georgia Ragia, Vangelis G Manolopoulos
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. Pharmacogenomics 21 (18) (2020)